This disclosure is a response from Dr. Reddy's Laboratories Ltd. to an email dated November 3, 2026, from BSE Surveillance (BSE Limited). The exchange sought clarification regarding a news article published on November 3, 2026, on the First Post website. The article was captioned "India's Dr Reddy's gets US nod for $40 generic HIV prevention shot for 120 poorer countries".
The company confirms that the headline of the news item is correct. The news pertains to the company's own press release dated November 2, 2026, titled "U.S. FDA grants tentative approval for Dr. Reddy's twice-yearly injectable lenacapavir, advancing access to HIV prevention across 120 countries outside the US."
The company explicitly states that, in its view, this matter "does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations." It affirms its commitment to complying with Regulation 30 by making timely disclosures of all events and information it considers material.
The letter is signed by K Randhir Singh, Company Secretary, Compliance Officer and Head-CSR, and is dated November 4, 2026.